Table 2.

Overall survival comparison between the NOA-08 study and CCTG CE.6/EORTC 26062

Population	NOA-08		CCTG CE.6/EORTC 26062*
Overall Survival	N	Months (95% CI)	N	Months (95% CI)
All patients
TMZ (+RT*)	195	8.2 (7.0–10.0)	281	9.3 (8.3–10.3)
RT	178	9.4 (8.1–10.4)	281	7.6 (7.0–8.4)
HR		0.93 (0.76–1.15)		0.67 (0.56–0.80)
Patients with MGMT−
TMZ (+RT*)	79	6.7 (5.6–8.2)	93	10.0 (8.3–10.7)
RT	60	10.2 (8.0–12.0)	96	7.9 (6.9–10.0)
HR		1.33 (0.95–1.87)		0.75 (0.56–1.01)
Patients with MGMT+
TMZ (+RT*)	39	18.4 (13.9–24.4)	88	13.5 (10.2–15.3)
RT	43	9.6 (6.4–13.7)	77	7.7 (5.8–10.7)
HR		0.44 (0.27–0.70)		0.53 (0.38–0.73)

*For NOA-08 TMZ alone, for CCTG CE.6/EORTC 26062 TMZ + RT is shown.